Source:http://linkedlifedata.com/resource/pubmed/id/19406277
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2009-5-1
|
| pubmed:abstractText |
Pulmonary arterial hypertension associated with congenital heart disease caused by systemic-to-pulmonary shunting was associated with a high risk of morbidity and mortality. In this retrospective study, the longer term treatment effect of bosentan on exercise capacity and quality of life (QoL) were evaluated in 58 adult patients (>18 years) with pulmonary arterial hypertension associated with congenital heart disease, including patients with Down's syndrome. All patients were evaluated at baseline and during follow-up using laboratory tests, 6-minute walk test, QoL questionnaires, and Doppler echocardiography. Treatment efficacy was analyzed separately for patients without (n = 30) and with Down's syndrome (n = 28). Median follow-up of all patients treated with bosentan was 22 months (range 3 to 36). In patients without Down's syndrome, mean 6-minute walk distance increased from 427 +/- 97 to 461 +/- 104 m (p <0.01) after 6 months of treatment, followed by a gradual return to baseline and disease stabilization. QoL improved significantly during treatment and was maintained during 18 months of follow-up (p <0.05). In patients with Down's syndrome, 6-minute walk distance and QoL were stable during treatment. In conclusion, findings suggested that in patients without Down's syndrome, longer term bosentan treatment resulted in a persistent improvement in QoL and stabilization of exercise capacity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1879-1913
|
| pubmed:author |
pubmed-author:BergerRolf M FRM,
pubmed-author:BoumaBerto JBJ,
pubmed-author:BresserPaulP,
pubmed-author:DuffelsMariëlle G JMG,
pubmed-author:HoendermisElke SES,
pubmed-author:MulderBarbara J MBJ,
pubmed-author:NieuwkerkPythia TPT,
pubmed-author:VisJeroen CJC,
pubmed-author:de Bruin-BonRianne H A C MRH,
pubmed-author:van DijkArie P JAP,
pubmed-author:van LoonRosa L ERL
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
1
|
| pubmed:volume |
103
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1309-15
|
| pubmed:meshHeading |
pubmed-meshheading:19406277-Adult,
pubmed-meshheading:19406277-Age Factors,
pubmed-meshheading:19406277-Aged,
pubmed-meshheading:19406277-Antihypertensive Agents,
pubmed-meshheading:19406277-Down Syndrome,
pubmed-meshheading:19406277-Exercise Test,
pubmed-meshheading:19406277-Exercise Tolerance,
pubmed-meshheading:19406277-Female,
pubmed-meshheading:19406277-Follow-Up Studies,
pubmed-meshheading:19406277-Heart Defects, Congenital,
pubmed-meshheading:19406277-Humans,
pubmed-meshheading:19406277-Hypertension, Pulmonary,
pubmed-meshheading:19406277-Magnetic Resonance Imaging,
pubmed-meshheading:19406277-Male,
pubmed-meshheading:19406277-Middle Aged,
pubmed-meshheading:19406277-Probability,
pubmed-meshheading:19406277-Quality of Life,
pubmed-meshheading:19406277-Retrospective Studies,
pubmed-meshheading:19406277-Risk Assessment,
pubmed-meshheading:19406277-Severity of Illness Index,
pubmed-meshheading:19406277-Sex Factors,
pubmed-meshheading:19406277-Sulfonamides,
pubmed-meshheading:19406277-Treatment Outcome,
pubmed-meshheading:19406277-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
|
| pubmed:affiliation |
Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands. m.g.duffels@amc.uva.nl
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Evaluation Studies
|